Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.
Antibody
COVID-19
ELISA
IgG
Inactivated virus
SARS-CoV-2
Journal
Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
03
08
2020
revised:
13
10
2020
accepted:
13
10
2020
pubmed:
31
10
2020
medline:
22
12
2020
entrez:
30
10
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2) continues to affect many countries and large populations. Serologic assays for antibody detection aid patient diagnosis and seroepidemiologic investigations. An indirect IgG ELISA was developed indigenously using β-propiolactone (BPL) inactivated SARS-CoV-2. This assay was used for screening 200 healthy donor sera collected prior to COVID-19 emergence (2017-2019), 185 serum/plasma samples of confirmed COVID-19 patients (n = 137) and 57 samples of viral RNA positive asymptomatic contacts (n = 51). The IgG response was studied in relation to duration and severity of illness. The ELISA demonstrated 97 % specificity and IgG detection in >50 %, 80 %, 93.8 % and 100 % of the patients respectively during the first, second, third and fourth week of illness. IgG detection rate was higher in patients with severe disease (SD, 90.9 %) than those with mild disease (MD, 68.8 %) during the second week of illness (P = 0.027). IgG seropositivity among asymptomatic contacts was 64.7 %. IgG ELISA absorbance values were higher in SD than MD patients during the first 2 weeks of illness (P < 0.05). No significant difference was observed between the absorbance values of asymptomatic subjects and MD patients (P = 0.94). The BPL inactivated virus-based ELISA could detect IgG antibodies early and in a significant proportion of COVID-19 patients suggesting its potential utility as a supplement to the currently used viral RNA detection tests in patient diagnosis and contact screening algorithms.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2) continues to affect many countries and large populations. Serologic assays for antibody detection aid patient diagnosis and seroepidemiologic investigations.
METHODS
An indirect IgG ELISA was developed indigenously using β-propiolactone (BPL) inactivated SARS-CoV-2. This assay was used for screening 200 healthy donor sera collected prior to COVID-19 emergence (2017-2019), 185 serum/plasma samples of confirmed COVID-19 patients (n = 137) and 57 samples of viral RNA positive asymptomatic contacts (n = 51). The IgG response was studied in relation to duration and severity of illness.
RESULTS
The ELISA demonstrated 97 % specificity and IgG detection in >50 %, 80 %, 93.8 % and 100 % of the patients respectively during the first, second, third and fourth week of illness. IgG detection rate was higher in patients with severe disease (SD, 90.9 %) than those with mild disease (MD, 68.8 %) during the second week of illness (P = 0.027). IgG seropositivity among asymptomatic contacts was 64.7 %. IgG ELISA absorbance values were higher in SD than MD patients during the first 2 weeks of illness (P < 0.05). No significant difference was observed between the absorbance values of asymptomatic subjects and MD patients (P = 0.94).
CONCLUSION
The BPL inactivated virus-based ELISA could detect IgG antibodies early and in a significant proportion of COVID-19 patients suggesting its potential utility as a supplement to the currently used viral RNA detection tests in patient diagnosis and contact screening algorithms.
Identifiants
pubmed: 33126149
pii: S0166-0934(20)30248-2
doi: 10.1016/j.jviromet.2020.113996
pmc: PMC7581401
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Propiolactone
6RC3ZT4HB0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113996Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Infect. 2020 Sep;81(3):435-442
pubmed: 32553841
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Virol. 2020 Aug;129:104529
pubmed: 32659710
Expert Rev Mol Diagn. 2020 May;20(5):453-454
pubmed: 32297805
Emerg Microbes Infect. 2020 Dec;9(1):1269-1274
pubmed: 32515684
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Clin Infect Dis. 2020 Nov 19;71(16):2066-2072
pubmed: 32357209
Clin Microbiol Infect. 2020 Aug;26(8):1082-1087
pubmed: 32473953
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
Indian J Med Res. 2020 May;151(5):444-449
pubmed: 32611915
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
J Infect Dis. 2020 Jun 29;222(2):183-188
pubmed: 32358956
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Med Virol. 2020 Jun 8;:
pubmed: 32510168
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057